GANX News and Press, Gain Therapeutics Inc. From 06/14/24

2024-06-14 04:35:45 ET More on Gain Therapeutics Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential Gain Therapeutics shares fall on proposed public offering Seeking Alpha’s Quant Rating on Gain Therapeutics Historical ...

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a public offering price of $1.35 per sha...

2024-06-13 16:56:00 ET More on Gain Therapeutics Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential Seeking Alpha’s Quant Rating on Gain Therapeutics Historical earnings data for Gain Therapeutics Financial information ...

2024-05-30 10:01:19 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...

BETHESDA, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announce...

2024-05-29 18:15:11 ET Summary Gain Therapeutics, Inc.'s drug candidate GT-02287 has best-in-class potential to slow or stop disease progression in Parkinson's disease. Gain is progressing at an impressive speed through its Phase 1 trial. Drug discovery engine Magellan, which ...

2024-05-14 13:54:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gain Therapeutics (NASDAQ: GANX ) just reported results for the first quarter of 2024. Gain Therapeutics reported earnings per share of -22 cents. This was above the analy...

2024-05-14 09:12:37 ET More on Gain Therapeutics Seeking Alpha’s Quant Rating on Gain Therapeutics Historical earnings data for Gain Therapeutics Financial information for Gain Therapeutics Read the full article on Seeking Alpha For further det...

BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports ...

Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...